A detailed history of Susquehanna International Group, LLP transactions in Heron Therapeutics, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 127,117 shares of HRTX stock, worth $213,556. This represents 0.0% of its overall portfolio holdings.

Number of Shares
127,117
Previous 318,712 60.12%
Holding current value
$213,556
Previous $1.12 Million 77.4%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.73 - $3.67 $331,459 - $703,153
-191,595 Reduced 60.12%
127,117 $252,000
Q2 2024

Aug 15, 2024

BUY
$2.32 - $3.86 $308,128 - $512,662
132,814 Added 71.44%
318,712 $1.12 Million
Q1 2024

May 07, 2024

BUY
$1.71 - $3.06 $199,510 - $357,019
116,673 Added 168.54%
185,898 $514,000
Q4 2023

Feb 14, 2024

SELL
$0.54 - $1.82 $61,893 - $208,602
-114,617 Reduced 62.35%
69,225 $117,000
Q3 2023

Nov 14, 2023

SELL
$0.97 - $1.8 $172,215 - $319,575
-177,542 Reduced 49.13%
183,842 $189,000
Q2 2023

Aug 11, 2023

BUY
$1.11 - $2.88 $36,306 - $94,201
32,709 Added 9.95%
361,384 $419,000
Q1 2023

May 16, 2023

SELL
$1.51 - $3.25 $10,346 - $22,269
-6,852 Reduced 2.04%
328,675 $496,000
Q4 2022

Feb 14, 2023

BUY
$2.25 - $4.67 $23,287 - $48,334
10,350 Added 3.18%
335,527 $838,000
Q3 2022

Nov 14, 2022

BUY
$2.66 - $5.37 $189,628 - $382,821
71,289 Added 28.08%
325,177 $1.37 Million
Q2 2022

Aug 15, 2022

SELL
$2.3 - $6.29 $328,389 - $898,073
-142,778 Reduced 35.99%
253,888 $708,000
Q1 2022

May 16, 2022

BUY
$4.63 - $9.94 $602,724 - $1.29 Million
130,178 Added 48.85%
396,666 $2.27 Million
Q4 2021

Feb 14, 2022

BUY
$8.35 - $12.6 $612,547 - $924,323
73,359 Added 37.98%
266,488 $2.43 Million
Q3 2021

Nov 15, 2021

BUY
$10.13 - $15.0 $363,758 - $538,635
35,909 Added 22.84%
193,129 $2.06 Million
Q2 2021

Aug 11, 2021

SELL
$13.27 - $18.48 $484,819 - $675,166
-36,535 Reduced 18.86%
157,220 $2.44 Million
Q1 2021

May 17, 2021

BUY
$14.49 - $20.72 $1.07 Million - $1.53 Million
73,978 Added 61.76%
193,755 $3.14 Million
Q4 2020

Feb 16, 2021

BUY
$14.61 - $22.14 $634,161 - $961,008
43,406 Added 56.84%
119,777 $2.54 Million
Q3 2020

Nov 16, 2020

SELL
$13.67 - $17.77 $959,579 - $1.25 Million
-70,196 Reduced 47.89%
76,371 $1.13 Million
Q2 2020

Aug 14, 2020

SELL
$10.89 - $21.47 $2 Million - $3.94 Million
-183,488 Reduced 55.59%
146,567 $2.16 Million
Q1 2020

May 15, 2020

BUY
$10.23 - $24.56 $2.33 Million - $5.58 Million
227,386 Added 221.47%
330,055 $3.88 Million
Q4 2019

Feb 14, 2020

SELL
$17.42 - $26.61 $1.46 Million - $2.23 Million
-83,660 Reduced 44.9%
102,669 $2.41 Million
Q3 2019

Nov 14, 2019

BUY
$16.36 - $21.39 $715,668 - $935,705
43,745 Added 30.68%
186,329 $3.45 Million
Q2 2019

Aug 16, 2019

BUY
$16.93 - $26.22 $381,957 - $591,549
22,561 Added 18.8%
142,584 $2.65 Million
Q2 2019

Aug 14, 2019

SELL
$16.93 - $26.22 $1.32 Million - $2.04 Million
-77,805 Reduced 39.33%
120,023 $2.23 Million
Q1 2019

May 15, 2019

BUY
$23.15 - $28.34 $3.84 Million - $4.7 Million
165,921 Added 520.01%
197,828 $4.84 Million
Q4 2018

Feb 14, 2019

SELL
$22.03 - $32.01 $43,839 - $63,699
-1,990 Reduced 5.87%
31,907 $828,000
Q3 2018

Nov 14, 2018

SELL
$30.0 - $40.85 $2.17 Million - $2.96 Million
-72,439 Reduced 68.12%
33,897 $1.07 Million
Q2 2018

Aug 14, 2018

BUY
$26.4 - $42.0 $1.62 Million - $2.58 Million
61,511 Added 137.22%
106,336 $4.13 Million
Q1 2018

May 15, 2018

SELL
$18.43 - $28.8 $3.95 Million - $6.18 Million
-214,557 Reduced 82.72%
44,825 $1.24 Million
Q4 2017

Feb 14, 2018

SELL
$14.8 - $18.85 $1.12 Million - $1.42 Million
-75,545 Reduced 22.56%
259,382 $4.7 Million
Q3 2017

Nov 14, 2017

BUY
$14.65 - $16.85 $4.91 Million - $5.64 Million
334,927
334,927 $5.41 Million

Others Institutions Holding HRTX

About HERON THERAPEUTICS, INC.


  • Ticker HRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 118,774,000
  • Market Cap $200M
  • Description
  • Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...
More about HRTX
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.